For nonalcoholic steatohepatitis, also known as NASH, a potential drug may treat the fatty liver disease in animal models researchers find.

Experts examine data from an NIH-funded study to determine if there is any racial disparity in hepatitis B treatment initiation in North America

BORGs, the TikTok trend hurting your liver. A Michigan Medicine liver doctor explains.

A 2011 FDA mandate to limit acetaminophen in combo opioid products led to a 13% y-o-y reduction in hospitalizations for serious liver injury.

A Michigan Medicine study may accelerate identifying patients who need liver transplants.

Nine years into her elementary school teaching career, LaKendra Butler was ready for anything. But, after experiencing severe pain in her side, she learned she would need a new liver.

Crohn’s disease, FODMAP, SUN1 gene and more: Research updates from Michigan Medicine clinicians.

A psychiatrist discusses the barriers to seeking help for alcohol use disorder and how to overcome them.

Study reveals Black Americans experience significant health inequities when receiving treatment for the cirrhosis-related disorder.

Alcohol-related liver disease is becoming more common in younger people, as 38-year-old Sara Nabors learned first-hand. Through innovative care from Michigan Medicine experts, she has taken her life back.

The increased number of deceased donor liver transplants related to alcoholic hepatitis — up more than 50 percent over predicted numbers — was associated with rising alcohol sales.

Like many newborns, Logan and Connor experienced mild jaundice after birth. As the weeks passed, Amy and Nick noticed Connor’s jaundice appeared to resolve, but Logan’s skin and eyes still appeared yellow. At nine weeks when Logan’s jaundice still hadn’t gone away, Amy and Nick grew concerned.

The human liver can regenerate, making living donor liver transplants possible. Michigan Medicine’s Transplant Center is one of only a few in the country offering this option.

The drug terlipressin is commonly used to treat hepatorenal syndrome in other parts of the world, but lacks FDA approval. Researchers examine both its efficacy and safety.

A pregnant liver transplant recipient receives cutting-edge monoclonal antibody treatment for COVID-19 months before her due date.